BeiGene (HKG:6160, SHA:688235) swung to a net loss of $121.4 million in the third quarter from a profit of $215.4 million in the year-ago period.
The drugmaker incurred a loss per share of $0.09, reversing earnings per share of $0.15 in the previous year, according to a Wednesday filing with the Hong Kong Exchange.
Total revenue jumped to $1 billion from $781.3 million a year earlier, driven by growth in BRUKINSA product sales in the US and Europe.
Shares slid 3% in Hong Kong during Wednesday's morning trading.
Price (HKD): $116.90, Change: $-4.9, Percent Change: -4.02%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。